A Space-Time Continuum for Immunotherapy Biomarkers in Gastroesophageal Cancer?

Abstract

In an annotated series of gastroesophageal adenocarcinomas differences in PD-L1 expression and tumor mutation burden occur between both paired contemporaneous primary and metastatic biopsies and pre/posttreatment samples. This work has implications for optimizing patient selection, serial testing, need for mechanistic understanding, and may underlie variable responses to checkpoint inhibitors in gastroesophageal cancers.<i>See related article by Zhou et al., p. 6453</i>.